Prostate cancer C61
Conditions
Interventions
Group 1: - PSMA-PET/CT for diagnosis and therapy planning in localised prostate carcinoma
- PSMA-PET/CT fusion biopsy in case of additional suspicious areas
- Biomarker determination PTEN, PSMA in the
Sponsors
Klinik und Poliklinik für Urologie und Kinderurologie Universitätsklinikum Bonn
Eligibility
Sex/Gender
Male
Age
45 Years to 75 Years
Inclusion criteria
Inclusion criteria: • The patient is suspected of having a localised prostate carcinoma based on at least one of the following criteria, so that clarification by means of MRI fusion punch biopsy is indicated: PSA-value = 4 ng/ml or suspicious tactile findings of the prostate in the digital rectal examination or suspicious findings in transrectal sonography • patients must be = 45 years and < 76 years old patients must be biopsy-naive • patient gives documented written consent to participate in the study • patients who are able to follow the study instructions and who are likely to adhere to all required study visits (compliance)
Exclusion criteria
Exclusion criteria: • The patient has a PSA level elevation of >100 ng/ml with resulting suspicion of advanced metastatic prostate carcinoma • The patient has a serious kidney disease, defined by Estimated creatinine clearance < 30 ml/min (using a site-specific method)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Optimising patients risk stratification with localised prostate cancer to improve therapy planning. | — |
Secondary
| Measure | Time frame |
|---|---|
| The combined use of PSMA-PET/CT in addition to standard procedure with mpMRT and histopathology is particularly aimed at increasing the detection rate of clinically significant cancer during prostate biopsy. | — |
Countries
Germany
Contacts
Public ContactPhilipp Krausewitz
Klinik und Poliklinik für Urologie und Kinderurologie Universitätsklinikum Bonn
Outcome results
None listed